Madrigal Pharmaceuticals (MDGL) announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases, AASLD Liver Meeting, taking place from November 15-19, 2024 in San Diego. Bill Sibold, Chief Executive Officer of Madrigal, stated, “This will be the first AASLD Liver Meeting following the approval of Rezdiffra earlier this year, and the entire NASH community feels energized with new momentum. It is an exciting moment for Madrigal and for the field as a whole. At the same time, we recognize that NASH remains the leading cause of liver transplant among women in the U.S. and second-leading cause in men, so there is an urgent need to continue advancing patient care. The Liver Meeting will provide a valuable opportunity to share the latest resmetirom clinical research, engage with healthcare providers, and reinforce Madrigal’s leadership position in NASH.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- MDGL Upcoming Earnings Report: What to Expect?
- Madrigal Pharmaceuticals price target lowered to $350 from $375 at Oppenheimer
- 3 Best Stocks to Buy Now, 10/23/2024, According to Top Analysts
- Madrigal Pharmaceuticals completes enrollment of study of Resmetirom
- Madrigal Pharmaceuticals management to meet with JMP Securities
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
